PhRMA and Epilepsy Foundation report finds more than 400 drugs in pipeline for neurological disorders

14 July 2015

There are currently 420 medicines in the American biopharma pipeline for neurological disorders, including epilepsy, Alzheimer’s and multiple sclerosis.

A new report from the Pharmaceutical Research and Manufacturers of America (PhRMA) and the Epilepsy Foundation shows scientists globally are collaborating to find new or more effective treatments for patients with central nervous system diseases.

Neurological disorders cover more than 600 conditions, including some for which there are few, if any, effective treatments.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK